LONDON, September 21, 2018 /PRNewswire/ --
Abingworth, the international investment group dedicated to life
sciences, today announced that Brian
Gallagher, PhD, will join Abingworth as a Partner based in
the company's Boston office. Brian
has more than 20 years of investing, business development,
operational and R&D experience in both biotechnology and large
pharmaceutical companies. He will work with the team in the
London and Menlo Park offices to source and support deals
across a wide range of therapeutic areas and stages of development
from start-ups to late-stage venture capital investments.
Brian joins from SR One, the venture capital arm of
GlaxoSmithKline (GSK), where he was a Partner and established the
company's Boston office.
Previously he was Senior Director of Corporate Development at
Sirtris Pharmaceuticals where he played a key role in post-merger
integration after the company's acquisition by GSK. Earlier in his
career, Brian held roles in R&D at Alantos Pharmaceuticals and
at Eisai. He holds a PhD in Organic Chemistry from the University of Michigan, is an inventor on over 25
patents and patent applications and is the senior author of a
number of publications in prominent journals.
"We are delighted to welcome Brian to Abingworth's team," said
Kurt von Emster, Managing Partner.
"Boston is a key life science
innovation centre and Brian's extensive investment experience,
network, and business oversight will add significantly to the
continued success and future of Abingworth."
"I am thrilled to join the Abingworth team at this exciting
time," said Brian Gallagher.
"Abingworth has a long and successful track record as a
transatlantic firm and I look forward to driving the next stage of
its growth, especially in the increasingly important life sciences
hub in Boston."
About Abingworth
Abingworth is an international investment group dedicated to
collaborating with life sciences entrepreneurs to develop their
ideas into products that have a dramatic impact on health. With
over $1.2 billion under management,
Abingworth invests at all stages of development, from start-ups to
publicly traded companies, and across all life science sectors.
Supporting its portfolio companies with a team of 25 at offices
in London, Menlo Park (California) and Boston, Abingworth has invested in 151 life
science companies, leading to 65 IPOs and 46 mergers and
acquisitions.
www.abingworth.com